Showing results (151-160 of 175) with videos related to
Sort By:
Pageof 18
The Lancet. Oncology|May 9, 2018
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trialSusanne Saussele, Johan Richter, Joelle Guilhot, et al.Nature Communications|April 21, 2018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic targetOlli Dufva, Matti Kankainen, Tiina Kelkka, et al.Nature Communications|February 22, 2019
Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapyHeidi M Haikala, Johanna M Anttila, Elsa Marques, et al.Nature Communications|January 2, 2025
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironmentBassel Alsaed, Linh Lin, Jieun Son, et al.Science Advances|April 30, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypesEmil Hiitola, Juuso Korhonen, Heidi Kokkonen, et al.Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.Nature Communications|February 8, 2019
Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapyHeidi M Haikala, Johanna M Anttila, Elsa Marques, et al.Blood|April 5, 2023
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic optionMonika Dolinska, Huan Cai, Alma Månsson, et al.Journal of Medicinal Chemistry|June 8, 2021
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic LeukemiaKrimo Toutah, Nabanita Nawar, Sanna Timonen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free RemissionFrancois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, et al.Pageof 18